Skip to Content

Alger Health Sciences Z AHSZX

Medalist Rating as of | See Alger Investment Hub
  • NAV / 1-Day Return 21.56  /  −0.37 %
  • Total Assets 109.1 Mil
  • Adj. Expense Ratio
    0.750%
  • Expense Ratio 0.750%
  • Distribution Fee Level Below Average
  • Share Class Type Institutional
  • Category Health
  • Investment Style Mid Growth
  • Min. Initial Investment 500,000
  • Status Open
  • TTM Yield
  • Turnover 306%

USD | NAV as of Apr 25, 2024 | 1-Day Return as of Apr 25, 2024, 10:10 PM GMT+0

Morningstar’s Analysis AHSZX

Will AHSZX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Alger Health Sciences Z earns a Morningstar Medalist Rating of Neutral with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings AHSZX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 47.4
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Amgen Inc

5.49 6.2 Mil
Healthcare

Vertex Pharmaceuticals Inc

5.29 6.0 Mil
Healthcare

Regeneron Pharmaceuticals Inc

5.21 5.9 Mil
Healthcare

Stryker Corp

5.19 5.8 Mil
Healthcare

Eli Lilly and Co

5.08 5.7 Mil
Healthcare

Boston Scientific Corp

5.04 5.7 Mil
Healthcare

Intuitive Surgical Inc

4.19 4.7 Mil
Healthcare

UnitedHealth Group Inc

4.13 4.6 Mil
Healthcare

McKesson Corp

4.06 4.6 Mil
Healthcare

Novo Nordisk A/S ADR

3.73 4.2 Mil
Healthcare